Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 8 | 2024 | 84 | 2.720 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 155 | 2.060 |
Why?
|
| Consensus | 4 | 2024 | 69 | 1.580 |
Why?
|
| HIV Infections | 2 | 2022 | 150 | 1.410 |
Why?
|
| Mouth Neoplasms | 2 | 2022 | 55 | 0.950 |
Why?
|
| Neoplasms | 3 | 2024 | 768 | 0.820 |
Why?
|
| Palliative Care | 1 | 2022 | 79 | 0.750 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 448 | 0.750 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2021 | 35 | 0.750 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 6 | 0.750 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 5 | 2023 | 64 | 0.730 |
Why?
|
| Proton Therapy | 1 | 2021 | 28 | 0.710 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 119 | 0.670 |
Why?
|
| Humans | 22 | 2024 | 27168 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 312 | 0.510 |
Why?
|
| Delphi Technique | 2 | 2024 | 17 | 0.460 |
Why?
|
| Endpoint Determination | 2 | 2024 | 17 | 0.460 |
Why?
|
| HIV | 2 | 2022 | 11 | 0.410 |
Why?
|
| Radiotherapy Dosage | 5 | 2024 | 102 | 0.370 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2021 | 60 | 0.360 |
Why?
|
| Terminology as Topic | 2 | 2024 | 53 | 0.280 |
Why?
|
| Margins of Excision | 2 | 2024 | 9 | 0.240 |
Why?
|
| Middle Aged | 6 | 2024 | 6913 | 0.240 |
Why?
|
| Cetuximab | 1 | 2024 | 20 | 0.240 |
Why?
|
| Brachytherapy | 2 | 2022 | 50 | 0.230 |
Why?
|
| Cisplatin | 1 | 2024 | 175 | 0.220 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2024 | 22 | 0.220 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 462 | 0.210 |
Why?
|
| Carcinoma | 1 | 2024 | 71 | 0.210 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2023 | 21 | 0.210 |
Why?
|
| Male | 6 | 2024 | 13041 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 318 | 0.200 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2022 | 12 | 0.200 |
Why?
|
| Thyroid Gland | 1 | 2022 | 31 | 0.200 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 40 | 0.200 |
Why?
|
| Retinal Detachment | 1 | 2022 | 10 | 0.200 |
Why?
|
| Eye Neoplasms | 1 | 2022 | 7 | 0.200 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 80 | 0.200 |
Why?
|
| Carboplatin | 1 | 2022 | 107 | 0.200 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2022 | 4 | 0.200 |
Why?
|
| Pyridazines | 1 | 2022 | 7 | 0.190 |
Why?
|
| Female | 8 | 2024 | 14662 | 0.190 |
Why?
|
| Radiation Injuries | 1 | 2022 | 51 | 0.190 |
Why?
|
| Quinazolines | 1 | 2022 | 31 | 0.190 |
Why?
|
| Prognosis | 1 | 2024 | 763 | 0.190 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 291 | 0.190 |
Why?
|
| Aged | 4 | 2024 | 5234 | 0.190 |
Why?
|
| Retinal Diseases | 1 | 2022 | 45 | 0.190 |
Why?
|
| Paclitaxel | 1 | 2022 | 184 | 0.190 |
Why?
|
| Metal Nanoparticles | 1 | 2023 | 128 | 0.190 |
Why?
|
| Macular Degeneration | 1 | 2022 | 79 | 0.180 |
Why?
|
| Retrospective Studies | 3 | 2024 | 2453 | 0.180 |
Why?
|
| Immunotherapy | 1 | 2022 | 143 | 0.180 |
Why?
|
| Intraoperative Care | 1 | 2020 | 22 | 0.180 |
Why?
|
| Mastectomy, Segmental | 1 | 2020 | 18 | 0.180 |
Why?
|
| Melanoma | 1 | 2022 | 128 | 0.180 |
Why?
|
| Quality of Life | 1 | 2024 | 468 | 0.180 |
Why?
|
| Breast | 1 | 2020 | 52 | 0.170 |
Why?
|
| Radiation Oncology | 2 | 2024 | 18 | 0.170 |
Why?
|
| Mammography | 1 | 2021 | 79 | 0.170 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 342 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 285 | 0.160 |
Why?
|
| Conjunctival Neoplasms | 1 | 2018 | 6 | 0.160 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2018 | 9 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 213 | 0.150 |
Why?
|
| Prospective Studies | 1 | 2020 | 1221 | 0.140 |
Why?
|
| Obesity | 1 | 2021 | 655 | 0.120 |
Why?
|
| Treatment Outcome | 1 | 2021 | 2286 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2024 | 19 | 0.120 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 65 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 98 | 0.110 |
Why?
|
| Chemoradiotherapy | 2 | 2024 | 43 | 0.100 |
Why?
|
| Decision Making | 1 | 2014 | 172 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 466 | 0.090 |
Why?
|
| Adult | 3 | 2024 | 7506 | 0.070 |
Why?
|
| Marijuana Use | 1 | 2024 | 32 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 38 | 0.060 |
Why?
|
| Cannabis | 1 | 2024 | 42 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 150 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2023 | 12 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2023 | 53 | 0.050 |
Why?
|
| Mice | 2 | 2023 | 4478 | 0.050 |
Why?
|
| Molecular Imaging | 1 | 2023 | 35 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 14 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 35 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 69 | 0.050 |
Why?
|
| Gold | 1 | 2023 | 129 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2024 | 862 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2022 | 206 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2022 | 251 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 934 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 965 | 0.040 |
Why?
|
| Animals | 2 | 2023 | 10093 | 0.040 |
Why?
|